Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma
Renate De Smedt(Ghent University), Pieter Van Vlierberghe(Ghent University Hospital), Lindy Reunes(Ghent University), Tim Lammens(Ghent University Hospital), Nadine Van Roy(Ghent University Hospital), Yves Benoît(Ghent University Hospital), Aurore Touzart(Inserm), Benedetta Accordi(University of Padua), Silvia Jenni(University Children's Hospital Zurich), Sofie Peirs(Ghent University Hospital), Valentina Serafin(University of Modena and Reggio Emilia), Lara Mussolin(Université Paris-Sud), Béatrice Lintermans(Ghent University Hospital), Dieter Deforce(Ghent University Hospital), Julie Morscio(VIB-KU Leuven Center for Cancer Biology), Juliette Roels, Jules P.P. Meijerink(Erasmus MC - Sophia Children’s Hospital), Birgit Burkhardt(University Hospital Münster), Giuseppe Basso(University of Padua), Federica Lovisa(Azienda Ospedaliera di Padova), Jean‐Pierre Bourquin(University Children's Hospital Zurich), Anne Uyttebroeck(Inserm), Barbara De Moerloose(Ghent University Hospital), Elizabeth Macintyre(Inserm), Filip Matthijssens(Argenx (Belgium)), Peter Vandenberghe(KU Leuven), Filip Van Nieuwerburgh(Ghent University Hospital), Thomas Tousseyn(KU Leuven), Beat Bornhäuser(University Children's Hospital Zurich), Yi-Chien Tsai, Steven Goossens(Ghent University)
Cited by 32
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
|Science|2003|3.5k